Arcutis Biotherapeutics, Inc. (ARQT) Tops Q2 EPS by 7c ; Offers Guidance

Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) reported Q2 EPS of $0.11, $0.07 better than the analyst estimate of $0.04. Revenue for the quarter came in at $129.9 million versus the consensus estimate of $117.54 million.

FY 2026 Outlook::-

Revenue between $525 million–$540 million vs consensus $500.1 million.

For earnings history and earnings-related data on Arcutis Biotherapeutics, Inc. (ARQT) click here.

You May Also Be Interested In

• Lucky Strike Entertainment Corporation (LUCK) reported Q2 Revenue ; Offers Guidance
• Fed’s Schmid says rates not restraining economy, hints at hikes
• SL Science licensor files FDA drug master file for GDT exosomes